The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan.
about
Genome-wide association study identifies single nucleotide polymorphism in DYRK1A associated with replication of HIV-1 in monocyte-derived macrophagesSafety, pharmacokinetics, and antiretroviral activity of multiple doses of ibalizumab (formerly TNX-355), an anti-CD4 monoclonal antibody, in human immunodeficiency virus type 1-infected adultsACTG (AIDS Clinical Trials Group) 384: a strategy trial comparing consecutive treatments for HIV-1HIV drug resistance and its impact on antiretroviral therapy in Chinese HIV-infected patientsThe individualized genetic barrier predicts treatment response in a large cohort of HIV-1 infected patientsA randomized trial of therapeutic drug monitoring of protease inhibitors in antiretroviral-experienced, HIV-1-infected patients.Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis.Association of efavirenz hypersusceptibility with virologic response in ACTG 368, a randomized trial of abacavir (ABC) in combination with efavirenz (EFV) and indinavir (IDV) in HIV-infected subjects with prior nucleoside analog experience.Virological and pharmacological parameters predicting the response to lopinavir-ritonavir in heavily protease inhibitor-experienced patients.Genotypic testing for human immunodeficiency virus type 1 drug resistance.Ritonavir-saquinavir dual protease inhibitor compared to ritonavir alone in human immunodeficiency virus-infected patients.Diversity and complexity of HIV-1 drug resistance: a bioinformatics approach to predicting phenotype from genotype.Virtual inhibitory quotient predicts response to ritonavir boosting of indinavir-based therapy in human immunodeficiency virus-infected patients with ongoing viremia.Clinical evaluation of the potential utility of computational modeling as an HIV treatment selection tool by physicians with considerable HIV experiencePharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients.HIV drug resistance detected during low-level viraemia is associated with subsequent virologic failureAccuracy of the TRUGENE HIV-1 genotyping kit.Local phylogenetic analysis identifies distinct trends in transmitted HIV drug resistance: implications for public health interventions.Evaluation of the editing process in human immunodeficiency virus type 1 genotyping.Geno2pheno: Estimating phenotypic drug resistance from HIV-1 genotypesThe development of drug resistance mutations K103N Y181C and G190A in long term Nevirapine-containing antiviral therapy.A Guide to HIV-1 Reverse Transcriptase and Protease Sequencing for Drug Resistance Studies.Surveillance of transmitted drug-resistant HIV among young pregnant women in Ouagadougou, Burkina Faso.Prevalence of transmitted HIV drug resistance among newly diagnosed antiretroviral therapy-naive pregnant women in Lilongwe and Blantyre, Malawi.Emerging trends of HIV drug resistance in Chinese HIV-infected patients receiving first-line highly active antiretroviral therapy: a systematic review and meta-analysis.HIV drug resistance testing by high-multiplex "wide" sequencing on the MiSeq instrument.Low Virologic Failure and Drug Resistance among HIV-Infected Patients Receiving Hospital-Based ART While Care and Outreach through Community in Guangxi, China.HIV-1 drug resistance in treatment-naive chronically infected patients in Jamaica.Predictive value of HIV-1 genotypic resistance test interpretation algorithms.The Genetic Basis of HIV-1 Resistance to Reverse Transcriptase and Protease Inhibitors.Pretreatment HIV-1 drug resistance is strongly associated with virologic failure in HIV-infected patients receiving partly active antiretroviral regimens.The use of computational models to predict response to HIV therapy for clinical cases in RomaniaThe case for addressing primary resistance mutations to non-nucleoside reverse transcriptase inhibitors to treat children born from mothers living with HIV in sub-Saharan Africa.Transmitted HIV drug resistance in treatment-naive Romanian patientsCost-effectiveness of newer antiretroviral drugs in treatment-experienced patients with multidrug-resistant HIV disease.High degree of interlaboratory reproducibility of human immunodeficiency virus type 1 protease and reverse transcriptase sequencing of plasma samples from heavily treated patientsVariants other than aspartic acid at codon 69 of the human immunodeficiency virus type 1 reverse transcriptase gene affect susceptibility to nuleoside analogs.Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients.An update to the HIV-TRePS system: the development and evaluation of new global and local computational models to predict HIV treatment outcomes, with or without a genotypePerformance characteristics of the TRUGENE HIV-1 Genotyping Kit and the Opengene DNA Sequencing System.
P2860
Q21135536-7B73E4D4-5955-4B49-BFB8-3BD72B3D97A2Q24645675-9A6D79A5-F737-473B-BB77-58501CBB8618Q28362780-0F12EEB4-C9E4-4BE1-B93C-4249CF8FE1CDQ28486005-7083A8C1-E829-451F-BFF0-7D899391EFECQ28536153-53A27195-36E6-4045-8E6A-B44AEAB49299Q33559216-14DD14F5-54E2-4A54-BAA3-67201CE5220BQ33592278-6C3B9646-45D0-4D82-8449-815FBF4D70FFQ33649563-7E21EDCA-5E3B-421F-A392-6841A722B51DQ33769950-150E02DF-B9F5-43D3-849D-6B93CDB88749Q33906239-A2381AAE-4CAC-442D-A471-2EDA73F8ED94Q33983571-6F7C2882-4669-42C9-95BF-D21BD06C563AQ34032267-F38C9622-137E-42F3-9558-67E85F5FAE9FQ34253139-9564513B-6594-4DC7-BA03-04953B716B2CQ34539475-EADC1154-DA38-45DB-A6DD-4D9629DE7120Q34720072-ED7C8BF1-793E-4059-B254-A5C7563D04D9Q34781706-6A7F4FF0-D49E-4FB4-989D-7EDAA557BC6AQ34972796-4B9D6774-010D-4661-92FA-B779F7D9CAA5Q35028707-72D75890-F188-4671-8BCC-A3DFC6C713BAQ35156934-952AFBC7-483A-4A1E-9927-A24928289934Q35208107-E6E8F2C6-2239-4945-AA7E-C505B913D9D4Q35552675-D5543EC7-706F-48E2-A51A-7E0E4708DE5EQ35742512-B956B84B-F404-42A2-B413-BEA3CE0B6C5CQ35917550-F4FC6284-8CFA-42AE-833A-C19E112402F6Q35917559-6A266B7E-584E-43F5-AA77-23E8080DD2E9Q36047681-3F800932-5F7A-4390-9ED6-913AFD7A1ADCQ36158371-213FD4A1-CB3A-4FF1-B633-7BBC16FE5496Q36209093-F03BC2B7-7E9E-40BC-8200-4DB8ACFD7B86Q36290017-B71C7617-AA7B-49C9-B4A6-A40DD5528743Q36641563-5A091048-B764-4BD9-8A61-5FDD42DE4846Q37018369-81BC7EA5-B7B5-4CEB-A9A8-AE777345508BQ37173887-EBCBD18C-DA41-4443-978E-227AA1BD25EDQ37441529-41AD6215-2EA1-4A2F-A6E4-912824EA1F48Q37491651-1B2817C5-81DA-4861-9A01-92401712DC8DQ37495405-04CEBE28-B54B-422C-8210-4F716E3A80F1Q37598398-EB003E57-440D-4A14-ADD8-D8FD70F930B8Q39464193-FC27046D-F68E-4C4F-9357-F73626D1ACB8Q39477972-E2E65D8B-6D93-425F-8468-027E85025F25Q39606435-F17C2AE3-8446-46C3-AB41-4B3CE1FA8761Q39665413-80734306-0B4A-4C7E-B85F-7EA65E78D785Q39748231-92B61342-8AA6-4C45-93B8-903CBDD12515
P2860
The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan.
description
2000 nî lūn-bûn
@nan
2000 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի մարտին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
The relation between baseline ...... andardized data analysis plan.
@ast
The relation between baseline ...... andardized data analysis plan.
@en
type
label
The relation between baseline ...... andardized data analysis plan.
@ast
The relation between baseline ...... andardized data analysis plan.
@en
prefLabel
The relation between baseline ...... andardized data analysis plan.
@ast
The relation between baseline ...... andardized data analysis plan.
@en
P2093
P1433
P1476
The relation between baseline ...... tandardized data analysis plan
@en
P2093
Ait-Khaled M
Castillo S
Clevenbergh P
D'Aquila R
DeGruttola V
Harrigan R
P577
2000-03-01T00:00:00Z